Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Advanced
Wish Lists Wish Lists
Wish Lists Wish Lists
Wish Lists
Cart Cart
Cart Cart
Cart
Sign in
Sign in
Contact us
Advanced
Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
CAMBRIDGE, MA, USA I February 7, 2018 I Sage Therapeutics (NASDAQ.
Just two drugmakers left bidding for Sanofi's European generics business
Just two drugmakers left bidding for Sanofi's European generics business
It has emerged that the number of industry players in the running to buy Sanofi’s (Euronext.
Array of excitement at combo’s comparison with Roche drug
Array of excitement at combo’s comparison with Roche drug
USA-based Array BioPharma (Nasdaq.
Boston’s Intarcia Pink Slips 60 Employees, Terminates Two Late-Stage Trials
Boston’s Intarcia Pink Slips 60 Employees, Terminates Two Late-Stage Trials
While Boston-based Intarcia Therapeutics grapples with addressing concerns raised by the U.
Apalutamide Delays Metastasis by Over 2 Years in Prostate Cancer
Apalutamide Delays Metastasis by Over 2 Years in Prostate Cancer
Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to findings from the phas...
Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
DUBLIN , Feb.
Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with High Tumor Mutation Burden (TMB)
Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with High Tumor Mutation Burden (TMB)
PRINCETON, N.
Amneal launches generic Concerta
Amneal launches generic Concerta
Amneal Pharmaceuticals has introduced its generic Concerta (methylphenidate hydrochloride extended-release) tablets.
Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
LOS ANGELES, Feb.
BRIEF—Heads of China FDA and Britain’s MHRA discuss cooperation
BRIEF—Heads of China FDA and Britain’s MHRA discuss cooperation
On February 1, 2018, Bi Jingquan, Minister of the China Food and Drug Administration (CFDA), met with the visiting Dr Ian Hudson, the chief executive of the UK’s Medicines and Healthcare pro...
CDC Director Brenda Fitzgerald resigns
CDC Director Brenda Fitzgerald resigns
(CNN) - Dr.
Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline
Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline
BOTHELL, Wash.
0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Custom chemistry. Chemistry FTE. Resynthesis.
Hit Follow up Support
Medicinal chemistry FTE
In silico drug design (CADD)
Discovery Biology. Biology FTE. In vitro studies.
Animal models
Toxicology and safety
ADME, DMPK. In vivo studies
Chemistry, manufacturing and controls
Company
News & Media
Contact us
Trends in discovery compounds